More on IMRX
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $4.85 |
|
|||
| Open | $4.85 | ||||
| 52 Wk High | $0.04 | ||||
| 52 Wk Low | $0.00 | ||||
| Day High | $4.85 | ||||
| Day Low | $4.85 | ||||
| P/E | N/A | ||||
| EPS | $-0.09 | ||||
| Volume | 498 | ||||
- H.C. Wainwright Reiterates Buy Rating on Immuneering Corporation (IMRX)
- Immuneering touts Phase 3 trial as FDA clears new pancreatic cancer drug
- Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients
- H.C. Wainwright Starts Immuneering Corporation (IMRX) at Buy
- Immuneering Corporation (IMRX) Reports In-Line Q2 EPS
- Form 10-Q Immuneering Corp For: Jun 30
- Form 8-K Immuneering Corp For: Aug 05
- Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates
- Form SCHEDULE 13G Immuneering Corp Filed by: BlackRock, Inc.
- Immuneering publishes preclinical data on atebimetinib in Cancer Research
Entities mentioned with IMRX
- FDA | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Earnings | View Related Stories »
- 13G | View Related Stories »
- IPO | View Related Stories »
- Jefferies & Co | View Related Stories »
- Show More...
